AcuCort is granted trademark protection in the US for its drug ISICORT®
AcuCort AB (Spotlight Stock Market: ACUC) today announced that the United States Patent and Trademark Office (USPTO) has granted the company’s drug ISICORT® trademark protection. AcuCort has an active strategy for the company’s trademarks that covers all major geographic markets, including the US.
ISICORT® is a thin, fast-dissolving and user-friendly oral film for the treatment of acute and severe allergic reactions, for croup in children and chemotherapy-induced nausea and vomiting (CINV). The fast-dissolving oral film contains the glucocorticoid dexamethasone which is a well-known, often used and well-documented anti-inflammatory substance. In October 2020, ISICORT® received market approval by the Swedish Medical Products Agency.
“We are very pleased that AcuCort has been granted trademark protection for ISICORT® in the USA. The decision means that we now have a registered trademark with associated trademark protection in the world's largest pharmaceutical market. Furthermore, our partner dialogues, preparations for commercialization and the work to achieve market approval in more markets continues as planned, says Jonas Jönmark, CEO of AcuCort AB.
The information was submitted for publication, through the agency of the contact person below, on March 3, 2021.
For more information, please contact
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
Email: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort develops and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy-induced nausea and vomiting (CINV). In February 2021, the Swedish Medical Products Agency (MPA) granted ISICORT® the indication – treatment of COVID-19 in patients who need supplemental oxygen treatment. The bioequivalence study that forms the basis of the application for market approval in Europe was carried out with positive results and the Swedish national application was approved by the Swedish MPA in October 2020. Altogether, this strengthens the company’s assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.com.
Tags: